Latest Period
Q4 2025
Security Snapshot
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) Institutional Ownership
CUSIP: 10806X102
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
427
Shares (Excl. Options)
188,213,795
Price
$76.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- BBIO on Nasdaq
- Shares outstanding
- 201,803,957
- Price per share
- $74.14
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 188,213,795
- Total reported value
- $14,404,255,681
- % of total 13F portfolios
- 0.02%
- Share change
- +653,090
- Value change
- +$187,214,916
- Number of holders
- 427
- Price from insider filings
- $74.14
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 10806X102.
- 427 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 427 to 239 between Q4 2025 and Q1 2026.
- Reported value moved from $14,404,255,681 to $3,578,322,543.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 427 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 10806X102?
CUSIP 10806X102 identifies BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 10806X102:
Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. | 7% | -31% | $476,864,517 | -$215,760,000 | 13,260,971 | -31% | KKR Genetic Disorder L.P. | 12 May 2025 |
| VIKING GLOBAL INVESTORS LP | 6.1% | -10% | $880,129,695 | -$87,989,901 | 11,842,434 | -9.1% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 5.7% | $845,275,116 | 11,000,457 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| Kumar Neil | 4.6% | -16% | $689,354,243 | -$87,903,790 | 9,282,982 | -11% | NEIL KUMAR | 31 Mar 2026 |
As of 31 Dec 2025, 427 institutional investors reported holding 188,213,795 shares of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO). This represents 93% of the company’s total 201,803,957 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 8.4% | 16,862,691 | +0.18% | 0.02% | $1,289,827,235 |
| BlackRock, Inc. | 7.2% | 14,549,529 | +0.96% | 0.02% | $1,112,893,458 |
| VIKING GLOBAL INVESTORS LP | 7.1% | 14,393,934 | -9.9% | 2.9% | $1,100,992,012 |
| Kohlberg Kravis Roberts & Co. L.P. | 6.6% | 13,260,971 | 0% | 16% | $1,014,331,672 |
| JANUS HENDERSON GROUP PLC | 5.5% | 11,000,457 | +26% | 0.38% | $841,348,639 |
| FARALLON CAPITAL MANAGEMENT LLC | 4.5% | 8,998,463 | +9.8% | 4% | $688,292,435 |
| Aisling Capital Management LP | 2.5% | 5,089,611 | -16% | 81% | $389,304,345 |
| STATE STREET CORP | 2.5% | 4,962,866 | -11% | 0.01% | $379,609,620 |
| Invesco Ltd. | 2.4% | 4,831,305 | +23% | 0.06% | $369,546,521 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 4,412,523 | +13% | 0.02% | $344,688,555 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 3,828,746 | +144% | 0.03% | $292,862,000 |
| Frazier Life Sciences Management, L.P. | 1.8% | 3,545,557 | -7.8% | 7.3% | $271,199,655 |
| FMR LLC | 1.2% | 2,390,362 | +41% | 0.01% | $182,838,766 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.2% | 2,348,731 | +130% | 0.03% | $179,654,434 |
| D. E. Shaw & Co., Inc. | 1.1% | 2,214,031 | -1.7% | 0.13% | $169,351,231 |
| FRANKLIN RESOURCES INC | 1.1% | 2,164,928 | +50% | 0.04% | $165,595,356 |
| ALLIANCEBERNSTEIN L.P. | 1% | 2,050,746 | -12% | 0.05% | $156,861,562 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.98% | 1,975,315 | +3.2% | 0.12% | $151,011,883 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.97% | 1,964,419 | +2% | 0.02% | $150,258,409 |
| TWO SIGMA INVESTMENTS, LP | 0.96% | 1,947,047 | -16% | 0.22% | $148,929,625 |
| Capital Research Global Investors | 0.96% | 1,934,698 | +0.08% | 0.03% | $147,985,050 |
| UBS Group AG | 0.93% | 1,875,665 | -27% | 0.03% | $143,469,616 |
| SC US (TTGP), LTD. | 0.92% | 1,860,364 | 0% | 1% | $142,299,242 |
| GOLDMAN SACHS GROUP INC | 0.88% | 1,782,833 | -19% | 0.02% | $136,368,897 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.85% | 1,725,266 | 0% | 0.2% | $131,966,000 |
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 48,180,090 | $3,578,322,543 | +$43,924,927 | $74.26 | 239 |
| 2025 Q4 | 188,213,795 | $14,404,255,681 | +$187,214,916 | $76.49 | 427 |
| 2025 Q3 | 184,963,434 | $9,606,937,258 | -$158,160,333 | $51.94 | 389 |
| 2025 Q2 | 188,818,044 | $8,154,464,813 | +$171,957,099 | $43.18 | 357 |
| 2025 Q1 | 185,173,982 | $6,405,659,483 | +$325,204,372 | $34.57 | 302 |
| 2024 Q4 | 176,645,317 | $4,847,193,349 | +$87,655,048 | $27.44 | 260 |
| 2024 Q3 | 172,596,886 | $4,393,814,683 | -$68,086,150 | $25.46 | 251 |
| 2024 Q2 | 174,953,530 | $4,431,556,073 | +$57,307,408 | $25.33 | 249 |
| 2024 Q1 | 171,539,419 | $5,303,582,949 | +$162,256,099 | $30.92 | 240 |
| 2023 Q4 | 165,715,337 | $6,690,573,516 | +$142,779,397 | $40.37 | 246 |
| 2023 Q3 | 161,102,840 | $4,243,730,776 | +$304,390,990 | $26.37 | 219 |
| 2023 Q2 | 149,815,028 | $2,576,329,186 | -$39,862,601 | $17.20 | 196 |
| 2023 Q1 | 152,372,388 | $2,526,139,807 | +$155,256,748 | $16.58 | 210 |
| 2022 Q4 | 144,623,389 | $1,101,997,850 | -$14,634,842 | $7.62 | 175 |
| 2022 Q3 | 145,248,661 | $1,443,911,522 | +$48,733,339 | $9.94 | 170 |
| 2022 Q2 | 140,449,294 | $1,275,283,327 | -$23,547,672 | $9.08 | 153 |
| 2022 Q1 | 143,303,557 | $1,454,787,082 | -$23,988,513 | $10.15 | 167 |
| 2021 Q4 | 141,976,495 | $2,367,117,577 | -$117,448,257 | $16.68 | 181 |
| 2021 Q3 | 140,028,398 | $6,563,888,337 | -$165,004,819 | $46.87 | 206 |
| 2021 Q2 | 142,676,491 | $8,697,122,835 | +$97,636,690 | $60.96 | 197 |
| 2021 Q1 | 141,085,070 | $8,688,930,801 | +$1,238,074,220 | $61.60 | 194 |
| 2020 Q4 | 121,079,579 | $8,609,553,572 | +$172,667,185 | $71.11 | 160 |
| 2020 Q3 | 117,841,767 | $4,393,419,330 | +$21,644,575 | $37.52 | 128 |
| 2020 Q2 | 117,300,177 | $3,824,660,106 | +$145,729,688 | $32.61 | 114 |
| 2020 Q1 | 112,894,365 | $3,273,779,385 | +$162,480,179 | $29.00 | 93 |
| 2019 Q4 | 100,520,271 | $3,523,336,508 | +$149,163,509 | $35.05 | 85 |
| 2019 Q3 | 103,303,295 | $2,217,864,724 | +$112,320,073 | $21.47 | 75 |
| 2019 Q2 | 99,927,998 | $2,695,534,750 | +$2,695,534,740 | $26.97 | 60 |